Recombinant Human Tumor necrosis factor ligand superfamily member 10(TNFSF10)

Code CSB-CF023985HU
Size Pls inquire
Source in vitro E.coli expression system
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Names TNFSF10
Uniprot No. P50591
Alternative Names Apo 2 ligand; APO 2L; Apo-2 ligand; Apo-2L; APO2L; CD253; CD253 antigen; Chemokine tumor necrosis factor ligand superfamily member 10; Protein TRAIL; TL2; TNF Related Apoptosis Inducing Ligand; TNF related apoptosis inducing ligand TRAIL; TNF-related apoptosis-inducing ligand; TNF10_HUMAN; TNFSF10; TRAIL; Tumor necrosis factor (ligand) family member 10; Tumor Necrosis Factor (ligand) Superfamily Member 10; Tumor necrosis factor apoptosis inducing ligand splice variant delta; Tumor necrosis factor ligand superfamily member 10
Species Homo sapiens (Human)
Expression Region 1-281
Target Protein Sequence MAMMEVQGGPSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMQDKYSKSGIACFLKEDDSYWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG
Protein Length full length protein
Tag Info The following tags are available.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form Lyophilized powder
Buffer before Lyophilization Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG
Gene References into Functions
  1. TRAIL protects against insulin resistance, NAFLD and vascular inflammation. Increasing TRAIL levels may be an attractive therapeutic strategy, to reduce features of diabetes, as well as liver and vascular injury, so commonly observed in individuals with NAFLD. PMID: 28507343
  2. data strongly suggest that XIAP-mediated inhibition of final caspase-3 processing is the last and major hurdle in TRAIL-induced apoptosis in NCI-H460 cells, which can be overcome by Smac in a Bcl-2 level dependent manner. PMID: 29927992
  3. Patients harboring the homozygous AA genotype of TRAIL SNPs rs1131568 and rs1131579 and the TT genotype of the TRAIL SNP rs1131580 had lower overall survival and higher rates of extrahepatic recurrence (EHR) than patients harboring the wild type or heterozygous genotypes. PMID: 30051596
  4. TRAIL synergistically sensitized irradiation-induced apoptosis in glioblastoma stem-like cells by increasing DR5 expression and decreasing cFLIP expression. PMID: 29777390
  5. Serum TRAIL concentrations are significantly reduced in patients with early preeclampsia. PMID: 29674187
  6. The combination treatment with ILz:rhTRAIL and bortezomib was able to induce cell death in both TRAIL-susceptible and TRAIL-resistant cancer cells through the intracellular TRAIL signaling pathway. The efficiency of cell death was dependent on the properties of TRAIL under the environment provided by bortezomib. The combination treatment-induced cell death was not regulated by bortezomib-induced ER stress response or by a PMID: 29661248
  7. A significant relationship was found between TRAIL polymorphisms and the susceptibility and severity of intervertebral disc degeneration in Han Chinese. PMID: 29284457
  8. High expression level of Galectin-3 and low expression level of TRAIL were found to be positively correlated with the shorter median survival time and overall survival time. PMID: 28925481
  9. Genes related to the extrinsic pathway of apoptosis including a receptor for TRAIL. PMID: 30061204
  10. Nelfinavir induces ER stress in renal cancer cells and sensitizes them to TRAIL. PMID: 30061216
  11. DR5-Cbl-b/c-Cbl-TRAF2 complex inhibited TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells. PMID: 28972304
  12. We found that the combination of alpha-mangostin with TRAIL induced apoptosis of SAS cells through the mitochondrial pathway via activation of caspase-9 and -3/7, following release of cytochrome c. This apoptosis was induced by S/G2/M-phase arrest. Immunopositivity for c-Myc was observed in the cytoplasm of tumor cells in 16 (40%) of the 40 cases of human oral squamous cell carcinoma (HOSCC). PMID: 29039600
  13. this study characterized in juvenile systemic lupus erythematosus a distinct profile from adult SLE that comprises increased sFas, sTRAIL, and reduced sFasL, notably in patients with active disease and with nephritis. PMID: 28378099
  14. Notch1 activation also suppressed A549 cell apoptosis by inhibiting the PI3K/pAkt pathway and activating the caspase-3 pathway in cooperation with TRAIL. Combining Notch1 signal with TRAIL inhibited PI3K, phosphorylated Akt and phosphorylated STAT3 expressions. PMID: 28718726
  15. we show that executioner caspase activation of the apoptotic nuclease CAD/DFF40 is essential for TRAIL-induced mutations in surviving cells. As exposure to chemotherapy drugs also activates apoptotic caspases and presumably CAD, we hypothesized that these pathways may also contribute to the mutagenesis induced by conventional chemotherapy drugs, perhaps augmenting the mutations that arise from direct DNA damage PMID: 28981092
  16. Cultured HCN-2 neurons were incubated at different times with GITRL and/or TRAIL, and thereafter nucleic acid and protein expression were measured. HCN-2 cells do not express GITRL mRNA, but the latter is induced after treatment with TRAIL. Cells did not express the GITRL receptor GITR mRNA, neither in control cultures, nor after treatment with TRAIL. TRAIL, when associated to GITRL, exerted additive toxic effects. PMID: 28524007
  17. DR5 has a dual role in death and survival signaling, which results in TRAIL resistance in cancer cells. PMID: 29048428
  18. Dynamin isoforms differentially regulate the endocytosis and apoptotic signaling downstream of TRAIL-death receptor (TRAIL-DR) complexes in cancer cells. TRAIL stimulation activates ryanodine receptor-mediated calcium release from endoplasmic reticulum stores, leading to calcineurin-mediated dephosphorylation and activation of Dyn1, TRAIL-DR endocytosis, and increased resistance to TRAIL-induced apoptosis. PMID: 28049841
  19. These results suggest that the FasL -844T>C single nucleotide polymorphism is implicated in the susceptibility to hepatitis C virus in Egyptian patients and firstly report the involvement of TRAIL gene polymorphism in the risk of the disease. PMID: 28587866
  20. ONC201 has potent antiproliferative and proapoptotic effects in a broad range of breast cancer subtypes, through TRAIL-dependent and TRAIL-independent mechanisms.The small-molecule ONC201 induces expression of TRAIL and its receptor DR5. ONC201 has entered clinical trials in advanced cancers. Here, we show that ONC201 is efficacious against both triple-negative breast cancers (TNBC) and non-TNBC cells PMID: 28424227
  21. our data suggest that nanoparticle-engineered TRAIL-expressing human adipose-derived stem cells exhibit the therapeutically relevant behavior of "seek-and-destroy" tumortropic migration and could be a promising therapeutic approach to improve the treatment outcomes of patients with malignant brain tumors. PMID: 27849590
  22. CaP@LDL-mediated STAT3-decoy ODN delivery might be a promising new strategy for reversing TRAIL resistance in hepatocellular carcinoma therapy. PMID: 29158840
  23. RA/poly(I:C) combination synergizes to induce a bioactive autocrine/paracrine loop of type-I Interferons (IFNs) which is ultimately responsible for TRAIL and TRAIL-R1/2 expression upregulation, while inhibition of TRAIL-R3/4 expression is type-I IFN-independent. PMID: 28409399
  24. our results demonstrated that nanovectorization of TRAIL with BNNTs enhanced its binding to both DR4 and DR5 receptors at 37 degrees C. Our novel nanovector could potentially be used for delivering TRAIL to cells for cancer treatment PMID: 28120533
  25. In primary hyperparathyroidism, hyperplasias demonstrated the highest expression of TRAIL and Fas, whereas in adenomas it was increased compared to normal tissue, but lower than in hyperplasias. PMID: 27763797
  26. Long-term toxicity test in cynomolgus monkeys did not cause rAAV2-sTRAIL95-281-related toxic and side effects, except that anti-AAV and anti-sTRAIL antibodies were generated. In conclusion, these data demonstrated that administration of rAAV2-sTRAIL95-281 in mice and in cynomolgus monkeys is safe without obvious toxic and side effects to the animals, and throw light on pharmacokinetics and safety in human clinical trials PMID: 28429751
  27. we found that plumbagin could enhance TRAIL-induced apoptosis in Kasumi-1 cells, and the mechanisms include ROS-mediated upregulation of DR5 expression, caspase-8 activation and inhibition of cFLIP expression PMID: 28498435
  28. None of these crude extracts exhibited cytotoxic effect on normal mouse embryonic fibroblasts (MEF), with the exception of EGY34. Analysis of the signaling pathways underlying the sensitization of MDA-MB-231 cells to TRAIL-induced apoptosis, by western blotting, revealed that all crude extracts facilitated initiator caspase8/-10 activation upon TRAIL stimulation PMID: 28440502
  29. Report a novel mechanism for the TRAIL-induced apoptosis of TrkAIII expressing NB cells that depends upon SHP/Src-mediated crosstalk between the TRAIL-receptor signaling pathway and TrkAIII. PMID: 27821809
  30. our findings identify a key role for c-Myc in TRAIL deregulation and as a biomarker of the anticancer action of HDACi in acute myeloid leukemia . PMID: 27358484
  31. Apoptosis induced by TRAIL is preferentially induced by TRAIL-R1 pathway in breast/lung tumor cells. PMID: 28039489
  32. These effects of metformin were accompanied by robust reductions in the protein levels of XIAP, a negative regulator of TRAIL-induced apoptosis. Silencing XIAP in TNBC cells mimicked the TRAIL-sensitizing effects of metformin. Metformin also enhanced the antitumor effects of TRAIL in a metastatic murine TNBC model PMID: 28324269
  33. siRNA silencing of CHOP significantly reduced cyproterone acetate-induced DR5 up-regulation and TRAIL sensitivity in prostate cancer cells. Our study shows a novel effect of cyproterone acetate on apoptosis pathways in prostate cancer cells and raises the possibility that a combination of TRAIL with cyproterone acetate could be a promising strategy for treating castration-resistant prostate cancer. PMID: 28270124
  34. TRAIL-armed exosomes can induce apoptosis in cancer cells. PMID: 26944067
  35. TRAIL expression in CTLs was negatively correlated with the expression of perforin and granzyme B, and negatively correlated with CTLs apoptosis in severe aplastic anemia patients. PMID: 28631177
  36. results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action PMID: 29182622
  37. UMI-77 enhances TRAIL-induced apoptosis by unsequestering Bim and Bak, which provides a novel therapeutic strategy for the treatment of gliomas. PMID: 28337703
  38. These results reveal KDM4A as a key epigenetic silencer of TRAIL and DR5 in tumors. PMID: 27612013
  39. Low Trail expression is associated with esophageal cancer. PMID: 29055676
  40. Results show that TNF-Related Apoptosis Inducing Ligand (TRAIL/TNFSF10) mRNA level correlates with T4 effector-memory lymphocytes (T4EM) lymphocytes radiosensitivity. PMID: 26982083
  41. Imbalance of the apoptosis pathway, with dysregulation of p73 and TRAIL, seems to play a role in the oncogenesis of odontogenic tumors PMID: 28025428
  42. hepatitis B virus (HBV) X protein (HBx) restricts TNFSF10 receptor signaling via macroautophagy/autophagy-mediated degradation of TNFRSF10B/DR5, a TNFSF10 death receptor. PMID: 27740879
  43. Findings suggest that loss of function of the human TRAIL promoter due to the SNP mutation leads to reduced expression and impaired inducibility of TRAIL, with the consequence of enhanced growth and migration of tumor cells, ultimately resulting in the progression of the hepatocellular carcinoma. PMID: 27580702
  44. these data show increased TRAIL mRNA expression in the airways and parenchyma in chronic obstructive pulmonary disease PMID: 26555706
  45. TRAIL expression is associated with thyroid hormone levels in vivo and TRAIL expression in peripheral blood mononuclear cells is stimulated by thyroid hormones in vitro. PMID: 28551332
  46. Antagonistic antibodies against the death receptors demonstrated that Apo2L/TRAIL mediated its apoptotic signals through activation of the TRAIL-R2 in PTHrP expressing breast cancer cells PMID: 23822995
  47. Co-treatment of carboplatin and autophagy inhibitor chloroquine increased lung tissue infiltration by CD4(+), FoxP3(+) lymphocytes and antigen-specific immune activation. Subsequent ex vivo experiments showed the activation of carboplatin related TRAIL-dependent apoptosis through caspase 8 and a synergistic role of miR-155 in lung tissue infiltration by CD4(+), and FoxP3(+) lymphocytes. PMID: 27692344
  48. Caspase-8 can serve in two distinct roles in response to TRAIL receptor engagement, as a scaffold for assembly of a Caspase-8-FADD-RIPK1 "FADDosome" complex, leading to NFkappaB-dependent inflammation, or as a protease that promotes apoptosis. PMID: 28212752
  49. Endogenous TRAIL/TRAIL-R-mediated CCL2 secretion promotes accumulation of tumor-supportive immune cells in the cancer microenvironment. PMID: 28212753
  50. BAY61-3606 sensitizes colon cancer cells to TRAIL-induced apoptosis by up-regulating DR4 expression in p53-dependent manner and inhibiting NF-kappaB activity. PMID: 27721019

Show More

Hide All

Subcellular Location Membrane, Single-pass type II membrane protein
Protein Families Tumor necrosis factor family
Tissue Specificity Widespread; most predominant in spleen, lung and prostate.
Database Links

HGNC: 11925

OMIM: 603598

KEGG: hsa:8743

STRING: 9606.ENSP00000241261

UniGene: Hs.478275

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1